The only study on CHEK2 and NMSC focused on BCC, finding a significant enrichment of CHEK2 mutations in patients with six or more BCCs compared with the ExAC non-Finnish European population, although only two mutations were identified owing to the small sample size [109]. This evidence concerns the gene CHEK2 and skin basal cell carcinoma.